Global PD-1 and PD-L1 Immunotherapy Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by PD-1 and PD-L1 Immunotherapy Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 PD-1 inhibitor
  • 1.4.3 PD-L1 inhibitor
• 1.5 Market by Application
  • 1.5.1 Global PD-1 and PD-L1 Immunotherapy Market Share by Application: 2020 VS 2026
  • 1.5.2 Solid Tumors
  • 1.5.3 Blood-related Tumors
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends by Regions

• 2.1 PD-1 and PD-L1 Immunotherapy Market Perspective (2015-2026)
• 2.2 PD-1 and PD-L1 Immunotherapy Growth Trends by Regions
  • 2.2.1 PD-1 and PD-L1 Immunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 PD-1 and PD-L1 Immunotherapy Historic Market Share by Regions (2015-2020)
  • 2.2.3 PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 PD-1 and PD-L1 Immunotherapy Market Growth Strategy
  • 2.3.6 Primary Interviews with Key PD-1 and PD-L1 Immunotherapy Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top PD-1 and PD-L1 Immunotherapy Players by Market Size
  • 3.1.1 Global Top PD-1 and PD-L1 Immunotherapy Players by Revenue (2015-2020)
  • 3.1.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio
  • 3.2.1 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Immunotherapy Revenue in 2019
• 3.3 PD-1 and PD-L1 Immunotherapy Key Players Head office and Area Served
• 3.4 Key Players PD-1 and PD-L1 Immunotherapy Product Solution and Service
• 3.5 Date of Enter into PD-1 and PD-L1 Immunotherapy Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global PD-1 and PD-L1 Immunotherapy Historic Market Size by Type (2015-2020)
• 4.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Type (2021-2026)

5 PD-1 and PD-L1 Immunotherapy Breakdown Data by Application (2015-2026)

• 5.1 Global PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)
• 5.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
• 6.2 PD-1 and PD-L1 Immunotherapy Key Players in North America (2019-2020)
• 6.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
• 6.4 North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
• 7.2 PD-1 and PD-L1 Immunotherapy Key Players in Europe (2019-2020)
• 7.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
• 7.4 Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

8 China

• 8.1 China PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
• 8.2 PD-1 and PD-L1 Immunotherapy Key Players in China (2019-2020)
• 8.3 China PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
• 8.4 China PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
• 9.2 PD-1 and PD-L1 Immunotherapy Key Players in Japan (2019-2020)
• 9.3 Japan PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
• 9.4 Japan PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
• 10.2 PD-1 and PD-L1 Immunotherapy Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
• 10.4 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

11 India

• 11.1 India PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
• 11.2 PD-1 and PD-L1 Immunotherapy Key Players in India (2019-2020)
• 11.3 India PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
• 11.4 India PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America PD-1 and PD-L1 Immunotherapy Market Size (2015-2020)
• 12.2 PD-1 and PD-L1 Immunotherapy Key Players in Central & South America (2019-2020)
• 12.3 Central & South America PD-1 and PD-L1 Immunotherapy Market Size by Type (2015-2020)
• 12.4 Central & South America PD-1 and PD-L1 Immunotherapy Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 AstraZeneca
  • 13.1.1 AstraZeneca Company Details
  • 13.1.2 AstraZeneca Business Overview and Its Total Revenue
  • 13.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Introduction
  • 13.1.4 AstraZeneca Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020))
  • 13.1.5 AstraZeneca Recent Development
• 13.2 Bristol-Myers Squibb
  • 13.2.1 Bristol-Myers Squibb Company Details
  • 13.2.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  • 13.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Introduction
  • 13.2.4 Bristol-Myers Squibb Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.2.5 Bristol-Myers Squibb Recent Development
• 13.3 F. Hoffmann-La Roche
  • 13.3.1 F. Hoffmann-La Roche Company Details
  • 13.3.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue
  • 13.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Introduction
  • 13.3.4 F. Hoffmann-La Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.3.5 F. Hoffmann-La Roche Recent Development
• 13.4 Merck
  • 13.4.1 Merck Company Details
  • 13.4.2 Merck Business Overview and Its Total Revenue
  • 13.4.3 Merck PD-1 and PD-L1 Immunotherapy Introduction
  • 13.4.4 Merck Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.4.5 Merck Recent Development
• 13.5 Pfizer
  • 13.5.1 Pfizer Company Details
  • 13.5.2 Pfizer Business Overview and Its Total Revenue
  • 13.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Introduction
  • 13.5.4 Pfizer Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.5.5 Pfizer Recent Development
• 13.6 Roche
  • 13.6.1 Roche Company Details
  • 13.6.2 Roche Business Overview and Its Total Revenue
  • 13.6.3 Roche PD-1 and PD-L1 Immunotherapy Introduction
  • 13.6.4 Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.6.5 Roche Recent Development
• 13.7 Novartis
  • 13.7.1 Novartis Company Details
  • 13.7.2 Novartis Business Overview and Its Total Revenue
  • 13.7.3 Novartis PD-1 and PD-L1 Immunotherapy Introduction
  • 13.7.4 Novartis Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.7.5 Novartis Recent Development
• 13.8 Jiangsu HengRui Medicine
  • 13.8.1 Jiangsu HengRui Medicine Company Details
  • 13.8.2 Jiangsu HengRui Medicine Business Overview and Its Total Revenue
  • 13.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Introduction
  • 13.8.4 Jiangsu HengRui Medicine Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.8.5 Jiangsu HengRui Medicine Recent Development
• 13.9 Innovent
  • 13.9.1 Innovent Company Details
  • 13.9.2 Innovent Business Overview and Its Total Revenue
  • 13.9.3 Innovent PD-1 and PD-L1 Immunotherapy Introduction
  • 13.9.4 Innovent Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.9.5 Innovent Recent Development
• 13.10 Eli Lilly
  • 13.10.1 Eli Lilly Company Details
  • 13.10.2 Eli Lilly Business Overview and Its Total Revenue
  • 13.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Introduction
  • 13.10.4 Eli Lilly Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 13.10.5 Eli Lilly Recent Development
• 13.11 GlaxoSmithKline
  • 10.11.1 GlaxoSmithKline Company Details
  • 10.11.2 GlaxoSmithKline Business Overview and Its Total Revenue
  • 10.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Introduction
  • 10.11.4 GlaxoSmithKline Revenue in PD-1 and PD-L1 Immunotherapy Business (2015-2020)
  • 10.11.5 GlaxoSmithKline Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer